Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07017803

Acronym

MESTCAR

Enrollment

460

Registered

2025-06-12

Start date

2025-07-01

Completion date

2026-01-31

Last updated

2025-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Africa, Molecular Epidemiology, Multi Drug Resistant Tuberculosis, Strains, Tuberculosis, Multi Drug Resistant

Brief summary

Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures. This is highlighted by the emergence of mutations encoding resistance to bed aquiline and quinolones which may impact the roll out of the newly recommended Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (BPaLM) regimens. It is also worth noting that there is increasing evidence of the significance of TB lineage in the outcome of infection, the approach in the study will provide both information on chains of transmission and lineage.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

9 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* All GeneXpert positive TB patients and participants who provide written informed consent will be screened for the study. Participants aged above 8 who can provide sputum will also be screened. * Patients enrolled in the tuberculosis epidemiology (TB-EPI) study and eligible for MESTCAR will be enrolled without any additional consent form as the data to be collected for the two studies will be shared and no additional process is needed.

Exclusion criteria

* Samples which do not meet the quality criteria. * Samples not enough to perform all of the laboratory process * Samples contaminated

Design outcomes

Primary

Measure	Time frame
Proportion of drug-resistant strains with characterised resistance mutations	6 months
Proportion of strains with new/undefined mutations among those with unexplained phenotypic resistance	6 months
Proportion of cases demonstrating transmission links, overall and between countries	6 months

Contacts

Primary ContactJabar Babatunde Pacome AGBO ACHIMI ABDUL

pacomeabdul@gmail.com+24177469843

Backup ContactRick elsy mirna NNOH DANSOU AKOUA

elsydansou@gmail.com+241 74474314

Outcome results